Immunome's Total Assets for the quarter that ended in Dec. 2024 was $240.24 Mil.
During the past 12 months, Immunome's average Total Assets Growth Rate was 120.60% per year.
During the past 3 years, the average Total Assets Growth Rate was 38.20% per year.
During the past 5 years, the average Total Assets Growth Rate was 43.10% per year.
During the past 7 years, Immunome's highest 3-Year average Total Assets Growth Rate was 45.10%. The lowest was 13.90%. And the median was 34.00%.
Total Assets is connected with ROA %. Immunome's annualizedROA % for the quarter that ended in Dec. 2024 was -129.14%. Total Assets is also linked to Revenue through Asset Turnover. Immunome's Asset Turnover for the quarter that ended in Dec. 2024 was 0.01.
Immunome Total Assets Historical Data
The historical data trend for Immunome's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Immunome's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Net Income data used here is four times the quarterly (Dec. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Immunome's Asset Turnover for the quarter that ended in Dec. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Immunome Total Assets Related Terms
Thank you for viewing the detailed overview of Immunome's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IMNM has been successfully added to your 